Epicardial Ablation in Brugada Syndrome to Prevent Sudden Death

Ventricular Arrhythmias and Cardiac Arrest Clinical Trial

Official title: Epicardial Ablation in Brugada Syndrome in the Prevention of Sudden Cardiac Death. A Randomized Prospective Follow-up Study.

Status Recruiting

Clinical Trial Summary

A total of 150 patients will be randomized to perform catheter ablation or not in a 2:1 fashion in selected patients with Brugada-related symptoms (Ablation+ICD arm 105 patients vs ICD only 45 patients).

Clinical Trial Description

The main purpose of this trial is to develop evidence-based curative treatment with optimal net benefit for patients with Brugada syndrome. As recent non-randomized pilot studies and scarce case reports documented the potential benefit of epicardial ablation, patients in this trial will be randomized to epicardial catheter ablation of the regions exhibiting abnormally prolonged and fragmented electrograms in the right ventricular outflow tract plus continued implanted cardioverter defibrillator therapy (ablation arm) or continued implanted cardioverter defibrillator therapy (control arm).

Survival from any ventricular arrhythmia (VA) recurrence will be considered as primary endpoint.

A projected 150 patients will be enrolled and randomized to receive ablation or not in a 2:1 fashion (Ablation+ICD arm 105 patients vs ICD only 45 patients). ;

Related Conditions & MeSH terms

• Brugada Syndrome
• Ventricular Arrhythmias and Cardiac Arrest

• NCT number: NCT03294278
• Study type: Interventional
• Source: IRCCS Policlinico S. Donato
• Contact: Carlo Pappone, MD
• Phone: +39 02 52774260
• Email: carlo.pappone@af-ablation.org
• Status: Recruiting
• Phase: N/A
• Start date: September 10, 2017
• Completion date: December 30, 2023